209 related articles for article (PubMed ID: 32329663)
21. Mitral Valve Prolapse: Multimodality Imaging and Genetic Insights.
Parwani P; Avierinos JF; Levine RA; Delling FN
Prog Cardiovasc Dis; 2017; 60(3):361-369. PubMed ID: 29122631
[TBL] [Abstract][Full Text] [Related]
22. Aldosterone Negatively Regulates Nrf2 Activity: An Additional Mechanism Contributing to Oxidative Stress and Vascular Dysfunction by Aldosterone.
Rodrigues D; Costa TJ; Silva JF; Neto JTO; Alves JV; Fedoce AG; Costa RM; Tostes RC
Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34200377
[TBL] [Abstract][Full Text] [Related]
23. Genome-Wide Association Study-Driven Gene-Set Analyses, Genetic, and Functional Follow-Up Suggest GLIS1 as a Susceptibility Gene for Mitral Valve Prolapse.
Yu M; Georges A; Tucker NR; Kyryachenko S; Toomer K; Schott JJ; Delling FN; Fernandez-Friera L; Solis J; Ellinor PT; Levine RA; Slaugenhaupt SA; Hagège AA; Dina C; Jeunemaitre X; Milan DJ; Norris RA; Bouatia-Naji N
Circ Genom Precis Med; 2019 May; 12(5):e002497. PubMed ID: 31112420
[TBL] [Abstract][Full Text] [Related]
24. Biomechanical evaluation of the pathophysiologic developmental mechanisms of mitral valve prolapse: effect of valvular morphologic alteration.
Choi A; McPherson DD; Kim H
Med Biol Eng Comput; 2016 May; 54(5):799-809. PubMed ID: 26307201
[TBL] [Abstract][Full Text] [Related]
25. Chromatin Accessibility of Human Mitral Valves and Functional Assessment of MVP Risk Loci.
Kyryachenko S; Georges A; Yu M; Barrandou T; Guo L; Bruneval P; Rubio T; Gronwald J; Baraki H; Kutschka I; Aras KK; Efimov IR; Norris RA; Voigt N; Bouatia-Naji N
Circ Res; 2021 Mar; 128(5):e84-e101. PubMed ID: 33508947
[TBL] [Abstract][Full Text] [Related]
26. Transesophageal echocardiographic assessment of the contribution of intrinsic tissue thickness to the appearance of a thick mitral valve in patients with mitral valve prolapse.
Louie EK; Langholz D; Mackin WJ; Wallis DE; Jacobs WR; Scanlon PJ
J Am Coll Cardiol; 1996 Aug; 28(2):465-71. PubMed ID: 8800127
[TBL] [Abstract][Full Text] [Related]
27. Activation of the mineralocorticoid receptor increases striatin levels.
Pojoga LH; Coutinho P; Rivera A; Yao TM; Maldonado ER; Youte R; Adler GK; Williams J; Turchin A; Williams GH; Romero JR
Am J Hypertens; 2012 Feb; 25(2):243-9. PubMed ID: 22089104
[TBL] [Abstract][Full Text] [Related]
28. Cardiac magnetic resonance in patients with mitral valve prolapse: Focus on late gadolinium enhancement and T1 mapping.
Pradella S; Grazzini G; Brandani M; Calistri L; Nardi C; Mori F; Miele V; Colagrande S
Eur Radiol; 2019 Mar; 29(3):1546-1554. PubMed ID: 30088066
[TBL] [Abstract][Full Text] [Related]
29. Site-related difference in the prevalence of mitral valve prolapse. Relation to the prevalence and severity of mitral regurgitation.
Murakami H; Yonekura S; Sudoh K; Hikita N; Nagao K; Takahashi N; Hashimoto A; Kijima T; Tanaka S; Shimamoto K
Jpn Heart J; 1991 Nov; 32(6):785-98. PubMed ID: 1811087
[TBL] [Abstract][Full Text] [Related]
30. NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury.
Bai M; Chen Y; Zhao M; Zhang Y; He JC; Huang S; Jia Z; Zhang A
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F556-F564. PubMed ID: 28052869
[TBL] [Abstract][Full Text] [Related]
31. Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.
Oyama MA; Elliott C; Loughran KA; Kossar AP; Castillero E; Levy RJ; Ferrari G
Cardiovasc Pathol; 2020; 46():107196. PubMed ID: 32006823
[TBL] [Abstract][Full Text] [Related]
32. Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease.
Mahimkar R; Nguyen A; Mann M; Yeh CC; Zhu BQ; Karliner JS; Lovett DH
Cardiovasc Pathol; 2009; 18(5):253-61. PubMed ID: 18835790
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of canine 2D cell cultures as models of myxomatous mitral valve degeneration.
Tan K; Markby G; Muirhead R; Blake R; Bergeron L; Fici G; Summers K; Macrae V; Corcoran B
PLoS One; 2019; 14(8):e0221126. PubMed ID: 31415646
[TBL] [Abstract][Full Text] [Related]
34. Postinflammatory mitral and aortic valve prolapse: a clinical and pathological study.
Tomaru T; Uchida Y; Mohri N; Mori W; Furuse A; Asano K
Circulation; 1987 Jul; 76(1):68-76. PubMed ID: 3594777
[TBL] [Abstract][Full Text] [Related]
35. Losartan inhibits endothelial-to-mesenchymal transformation in mitral valve endothelial cells by blocking transforming growth factor-β-induced phosphorylation of ERK.
Wylie-Sears J; Levine RA; Bischoff J
Biochem Biophys Res Commun; 2014 Apr; 446(4):870-5. PubMed ID: 24632204
[TBL] [Abstract][Full Text] [Related]
36. TGF-beta1 pathway activation and adherens junction molecular pattern in nonsyndromic mitral valve prolapse.
Rizzo S; Basso C; Lazzarini E; Celeghin R; Paolin A; Gerosa G; Valente M; Thiene G; Pilichou K
Cardiovasc Pathol; 2015; 24(6):359-67. PubMed ID: 26345253
[TBL] [Abstract][Full Text] [Related]
37. [The prevalence and clinical features of pathologically abnormal mitral valve leaflets (myxomatous mitral valve) in the mitral valve prolapse syndrome: an echocardiographic and pathological comparative study].
Takamoto T; Nitta M; Tsujibayashi T; Taniguchi K; Marumo F
J Cardiol Suppl; 1991; 25():75-86. PubMed ID: 1888468
[TBL] [Abstract][Full Text] [Related]
38. Echocardiographic assessment of mitral stenosis and its associated valvular lesions in 205 patients and lack of association with mitral valve prolapse.
Sagie A; Freitas N; Chen MH; Marshall JE; Weyman AE; Levine RA
J Am Soc Echocardiogr; 1997 Mar; 10(2):141-8. PubMed ID: 9083969
[TBL] [Abstract][Full Text] [Related]
39. The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes.
Gravez B; Tarjus A; Jimenez-Canino R; El Moghrabi S; Messaoudi S; Alvarez de la Rosa D; Jaisser F
PLoS One; 2013; 8(9):e73737. PubMed ID: 24040049
[TBL] [Abstract][Full Text] [Related]
40. Frequency and significance of M-mode echocardiographic evidence of mitral valve prolapse in clinically isolated pure mitral regurgitation: analysis of 65 patients having mitral valve replacement.
Waller BF; Maron BJ; Del Negro AA; Gottdiener JS; Roberts WC
Am J Cardiol; 1984 Jan; 53(1):139-47. PubMed ID: 6691250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
